The exercise period for subscription of shares through exercise of warrants of series TO5 begins today
NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, JAPAN, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SOUTH KOREA, CANADA, OR IN ANY OTHER JURISDICTION WHERE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER ACTIONS BEYOND THOSE REQUIRED BY SWEDISH LAW.
Today, 6 November 2024, the exercise period for warrants of series TO5 (“TO5”) in PEPTONIC medical AB ("Peptonic" or “the Company”) begins. The exercise period runs from and including November 6, 2024, until and including November 20, 2024. Each TO5 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.013. If all TO5 are exercised, the Company receives approximately SEK 27.4 million before issue costs. For TO5 to not expire without value, it is required that the holder actively subscribes for new shares no later than November 20, 2024, or dispose of their TO5 no later than November 15, 2024. Please observe that certain nominees might close their application earlier than November 20, 2024.
On 16 April 2024, the Board of Directors of Peptonic decided, subject to the subsequent approval of the Shareholders’ Meeting, on a rights issue of units consisting of shares and TO5. The decision was approved by the Annual General Meeting on 21 May 2024. Today, 6 November 2024, the exercise period for TO5 begins. Each TO5 entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 0.013. Full terms and conditions for TO5 are available on the Company's website: www.peptonicmedical.se.
If all TO5 are exercised, the Company will receive approximately SEK 27.4 million before issuing costs. For TO5 to not expire without value, it is required that the holder actively subscribes for new shares no later than November 20, 2024, or sell TO5 no later than November 15, 2024. Please observe that certain nominees might close their application earlier than November 20, 2024.
Summarized terms for TO5:
Exercise period: November 6, 2024 – November 20, 2024.
Issue size: 2,108,539,328 TO5, which entitles to subscription of 2,108,539,328 shares. If all TO5 are exercised, the Company will receive approximately SEK 27.4 million before issuing costs.
Exercise price: SEK 0.0013 per share.
Last day for trading in TO5: November 15, 2024.
Share capital and dilution: If all TO5 are exercised the share capital will increase with approximately SEK 14,759,775.51, from approximately SEK 40,288,242.09 to approximately SEK 55,048,017.60. If all TO5 are exercised the number of shares in the Company will increase with 2,108,539,328 shares, from 5,755,463,072 shares to 7,864,002,400 shares. In the event that all TO5 are exercised, the dilution amounts to approximately 26.81 percent of the number of existing shares in the Company.
Please note that TO5 that are not exercised on or before November 20, 2024, or sold on or before November 15, 2024, will expire without value. For TO5 not to lose their value, the holder must actively subscribe for new shares or sell TO5.
How TO5 are exercised:
Nominee-registered TO5 (Custody account)
Subscription and payment by exercise of TO5 shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.
Direct-registered TO5 (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. TO5 will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.
The application form including instructions for payment will be available at the Company’s website, www.peptonicmedical.se, and on Mangold Fondkommission AB’s website, www.mangold.se.
Advisers
Mangold Fondkommission AB is financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser to Peptonic in connection with the utilization of TO5.
For further information, please contact:
Anna Linton, CEO Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
Peptonic Medical AB (publ) is a cutting-edge Swedish biomedical company, dedicated in the development and distribution of clinically proven self-care treatments and self-diagnostic tests in intimate women's health. The portfolio is sold under the brands Vagivital and Vernivia. The company's vision is to revolutionize intimate health by empowering women to diagnose, treat, and prevent intimate medical conditions independently and effectively. Intimate health shall be natural, safe, and easy for women to manage on their own.
Central to Peptonic's growth strategy is the geographical expansion of VagiVital and Vernivia through local partners. Peptonic Medical also intends to continuously broaden its product portfolio through acquisitions and the development of innovative and competitive products in-house. The company's mousse-based drug delivery technology, Venerol, and the gel base in VagiVital create favorable conditions for expanding the portfolio.
The company is headquartered in Stockholm, Sweden, and has subsidiaries Common Sense Marketing Inc in the USA and Peptonic Medical Ltd in Israel. Peptonic Medical was founded in 2009, and the company's shares have been listed on the Spotlight Stock Market since 2014.
Important information
The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Peptonic in any jurisdiction, neither from Peptonic nor anyone else.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, South Africa, the United States, Belarus, or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.